EGFR and neoplasm: This approach helps overcome antigen loss and variability, as seen with EGFR variant III (EGFRvIII) CAR-T cells secreting BiTEs to target glioblastoma cells while activating bystander T cells, enhancing the antitumour response against heterogeneous tumours (191).